Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis : Partner Takeda Secures Cabometyx Combo Nod in Japan for Metastatic Renal Cell Cancer

08/25/2021 | 04:46pm EDT


© MT Newswires 2021
All news about EXELIXIS, INC.
10/19EXELIXIS : to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
BU
10/18INSIDER SELL : Exelixis
MT
10/15EXELIXIS : In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance ..
AQ
10/14EXELIXIS : Storm Therapeutics Sign Collaboration, License Deal to Discover Cancer Treatmen..
MT
10/14EXELIXIS : In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance ..
BU
10/14EXELIXIS : and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement..
BU
10/14Exelixis, Inc. Exercises Exclusive Option Under the Companies’ July 2019 Agreement
CI
10/07EXELIXIS : Jefferies Starts Exelixis at Buy with $28 Price Target
MT
09/20EXELIXIS : Reports Final Results From Phase 3 Trial of Thyroid Cancer Treatment
MT
09/20EXELIXIS : Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in ..
BU
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2021 1 392 M - -
Net income 2021 210 M - -
Net cash 2021 989 M - -
P/E ratio 2021 33,8x
Yield 2021 -
Capitalization 6 720 M 6 720 M -
EV / Sales 2021 4,12x
EV / Sales 2022 3,34x
Nbr of Employees 773
Free-Float 98,0%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 21,33 $
Average target price 31,46 $
Spread / Average Target 47,5%
EPS Revisions
Managers and Directors
Michael M. Morrissey President, Chief Executive Officer & Director
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Dana T. Aftab Executive Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.6.28%6 720
GILEAD SCIENCES, INC.14.98%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.25.77%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536